KNG1 Antikörper (Biotin)

Produktnummer ABIN6297826

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch KNG1 in WB und ELISA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für KNG1 Antikörper (Biotin) (ABIN6297826)

Target: KNG1 (Kininogen 1 (KNG1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser KNG1 Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-KNG1 Antikörper (Biotin)

Verwendungszweck: Rabbit anti-Human Bradykinin [+Biotin] Antibody,

Immunogen: This antibody was produced from antiserum of rabbits immunized with a polypeptide immunogen. The IgG fraction was purified by Protein G/A affinity chromatography.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA (recommended work dilution= 1:16,000), Western Blotting (recommended work dilution= 1:1,000-5,002),

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Rekonstitution: Product is supplied as a powder obtained from lyophilization of purified antibody in PBS without preservatives. Reconstitute the antibody with sterile 1 x PBS to a final concentration of 1 mg/mL.

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: -20°C

Details zu KNG1

Target: KNG1 (Kininogen 1 (KNG1))

Andere Bezeichnung: Kininogen-1 , Kininogen-1 light chain, Low molecular weight growth-promoting factor]

Hintergrund:

Target Description: Bradykinin is a potent endothelium-dependent vasodilator, leading to a drop in blood pressure. It also causes contraction of non-vascular smooth muscle in the bronchus and gut, increases vascular permeability and is also involved in the mechanism of pain.Bradykinin also causes natriuresis, contributing to the drop in blood pressure.Bradykinin raises internal calcium levels in neocortical astrocytes causing them to release glutamate.Bradykinin is also thought to be the cause of the dry cough in some patients on angiotensin-converting enzyme (ACE) inhibitor drugs. It is thought that bradykinin is converted to inactive metabolites by ACE, therefore inhibition of this enzyme leads to increased levels of bradykinin, which causes a dry cough via bronchoconstriction. This refractory cough is a common cause for stopping ACE inhibitor therapy, in which case angiotensin II receptor antagonists (ARBs) are the next line of treatment.Overactivation of bradykinin is thought to play a role in a rare disease called hereditary angioedema, formerly known as hereditary angio-neurotic edema.

Gene Symbol: KNG1///BDK///KNG

Gen-ID: 3827

UniProt: P01042

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process